NCT00544349已完成2 期
Phase II Study Evaluating the Effectiveness of the Association of Chemotherapy LV5FU2 Simplified and Cetuximab With Intra-arterial Hepatic Chemotherapy Using Oxaliplatin in Patients With Colorectal Cancer and Nonresectable Hepatic Metastases
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 7
- 主要终点
- Efficacy: objective tumor response rate (RECIST criteria)
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as leucovorin, fluorouracil, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving more than one drug (combination chemotherapy) and giving them together with cetuximab may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving leucovorin together with fluorouracil, cetuximab, and oxaliplatin works in treating patients with stage IV colorectal cancer and liver metastases that cannot be removed by surgery.
详细描述
OBJECTIVES:
Primary
- Determine the efficacy of this regimen by the measurement of objective response rate (RECIST criteria).
Secondary
- Determine the toxicity of this regimen.
- Evaluate the duration of tumor response.
- Determine the duration and rate of tumor control.
- Determine the rate of secondary resectability of hepatic metastases.
- Evaluate progression-free survival
- Determine rate of progression of the tumor.
- Determine overall survival.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed primary cancer of the colon or rectum
- •Isolated hepatic metastases
- •Not amenable to curative resection or requirement for complex and or larger (i.e., > 4 liver segments) liver resection
- •Measurable disease (RECIST criteria)
- •Original tumor must be (or have been) removed
- •PATIENT CHARACTERISTICS:
- •Inclusion criteria:
- •WHO performance status 0-1
- •Life expectancy > 3 months
- •ANC ≥ 1,500/mm³
- •Platelet count ≥ 100,000/mm³
- •Hemoglobin ≥ 9 g/dL
- •Creatinine ≤ 1.5 times normal
- •Bilirubin ≤ 1.5 times upper limit of normal
- •Transaminases ≤ 5 times normal
- •Not pregnant or nursing
- •Fertile patients must use effective contraception
排除标准
- •Contraindication or allergy grade 3-4 to any components of the study drugs
- •Peripheral neuropathy
- •Intestinal occlusion or subocclusion or prior inflammatory intestinal disease
- •Severe cardiac disease including any of the following:
- •Symptomatic coronary disease
- •Myocardial infarction in the past 6 months
- •New York Heart Association grade II-IV cardiac insufficiency
- •Severe arrhythmia (even if treated)
- •Active or uncontrolled infection
- •Other concurrent serious disorder
- •Severe uncontrolled medical condition
- •Other malignancy within the past 5 years or concurrently except basal cell skin cancer or carcinoma in situ of the cervix
- •Study impossible due to psychological, geographical, or social reasons
- •Prisoners or patients under guardianship
- •PRIOR CONCURRENT THERAPY:
- •Exclusion criteria:
- •Prior chemotherapy except adjuvant chemotherapy comprising fluorouracil, leucovorin calcium, capecitabine, oxaliplatin, irinotecan hydrochloride, and/or bevacizumab (completed > 6 months ago if oxaliplatin- or irinotecan-based)
- •Prior epidermal growth factor (EGF), monoclonal antibody inhibiting transduction of EGF receptor (EGFR), or any other treatment targeting the EGFR
- •Other concurrent anticancer immunotherapy, chemotherapy, or hormone therapy
- •Participation in another study in the past 30 days
结局指标
主要结局
Efficacy: objective tumor response rate (RECIST criteria)
次要结局
- Toxicity as assessed by NCI CTCAE v3.0
- Duration of response
- Duration and rate of tumor control
- Secondary resectability of hepatic metastases
- Progression-free survival
- Overall survival
- Tumor progression rate
研究者
研究点 (7)
Loading locations...
相似试验
终止
2 期
Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal CancerPrimary Peritoneal Cavity CancerColorectal CancerNCT00766142Institut Bergonié18
已完成
2 期
Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By SurgeryColorectal CancerNCT00321828NSABP Foundation Inc90
已完成
3 期
Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal CancerColorectal CancerPrimary Peritoneal Cavity CancerNCT00769405UNICANCER264
终止
2 期
Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction CancerEsophageal CancerNCT00551759Eastern Cooperative Oncology Group22
已完成
2 期
Oxaliplatin, Leucovorin, and Fluorouracil Before and After Radiation Therapy and Surgery in Treating Patients With Rectal Cancer That Can Be Removed by SurgeryColorectal CancerNCT01263171Cardiff University60